Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.
No news articles found for Lipella Pharmaceuticals.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
